Mayer Brown

May 21, 202416:00 – 19:00 BSTRegister here.

Join the Nasdaq Center for Board Excellence and connect with fellow board members and CEOs for a discussion about the transformative role of artificial intelligence, ethics, governance, and strategies for a competitive advantage. Together with Mayer Brown, we look forward to welcoming you and sharing enriching conversations to

Artificial intelligence (AI) is transforming the financial industry, and the derivatives market is no exception. A new whitepaper from ISDA Future Leaders in Derivatives (IFLD), a professional development program for emerging leaders in the derivatives market, explores the potential use of generative artificial intelligence (GenAI) in the derivatives markets. GenAI is a branch of AI that

Immunotherapy treatments such as antibodies targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1) and PD-1 ligand1 (PD-L1) have shown promise in reactivating weakened immune cells to fight cancer. While these immunotherapies have had a dramatic impact in some cancer patients, the positive results only appear in a fraction of cases.

Welcome to Immuno-Innovation, Mayer Brown’s blog reporting at the intersection of Immunotherapy and Intellectual Property law with legal analysis, updates on case law and legislative developments, as well as trend-spotting and best practices. Over the last twenty-five years, immunotherapy has been a fast-moving field (even if its newsworthy advances have appeared to proceed in increments),